araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention

Summary: The purpose of this study is to learn if a cervical health literacy program is a practical and helpful way of improving women's cervical health knowledge and improving cancer screening behaviors, and ultimately preventing cervical cancer.

Detailed description: Women in the criminal just system are 4-5 times more likely to have cervical cancer than non-incarcerated women. Little is known about how to close this gap. The few investigators that have studied cervical cancer risk and disease among women in jails and prisons have found that while many women get screened for cervical cancer, less than half get follow-up care.
  The investigator's pilot research suggests the most important contributor to cervical cancer risk, and perhaps lack of follow-up, is incarcerated women's low health literacy about both cervical cancer and broader reproductive health issues. This study is testing a sexual health empowerment intervention (SHE Project) to see if it improves incarcerated women's reproductive health literacy.

Eligibility: Inclusion Criteria:
  -  Women sentenced or anticipate a sentence of one year or less
  -  Ability to follow participants post-jail release
  -  Able to read and understand English
  Exclusion Criteria:
  -  Women who have been treated for cervical cancer with procedures that would obviate the need for regular screening
  -  Exhibit severe psychological distress

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor

Summary: As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising.
  The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.


Eligibility: Inclusion Criteria:
  -  Female aging from 16 to 75-year old;
  -  Preoperative diagnosis of gynecologic malignancies;
  -  Have the ability to comply with Research programs;
  -  Voluntarily participate in the study and signed an informed consent form
  Exclusion Criteria:
  -  The cases do not meet the inclusion criteria should be removed from,indicating the reason for excluding.

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

Summary: This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in patients with hypercholesterolemia and hypertension.


Eligibility: Inclusion Criteria:
  -  Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg
  -  or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg
  -  Fasting LDL-C between 100 and 220 mg/dL
  -  Fasting triglycerides less than 400 mg/dL
  -  Body mass index (BMI) between 18 and 45 kg/m2
  Exclusion Criteria:
  -  Known or suspected secondary hypertension or history of malignant hypertension
  -  Taking more than two anti-hypertension medications at the first visit
  -  History or current clinically significant cardiovascular disease
  -  History or current type 1 diabetes or type 2 diabetes

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Metformin Treatment in Polycystic Ovary Syndrome (PCOS)

Summary: PCOS occurs when a woman does not release an egg regularly each month, causing her periods to be irregular. Women with PCOS can also have increased hair growth on the face and body, acne, head balding, infertility, pre-diabetes, and diabetes. PCOS is commonly treated with oral contraceptive pills (also known as the birth control pills). Sometimes, a medication called metformin is also used to treat PCOS, especially if a woman has evidence of insulin resistance or if fertility is desired. Unfortunately, metformin works in only some women with PCOS. The mechanism through which metformin works in PCOS is not clear and it difficult to predict who will benefit from metformin treatment and who will not.
  The investigators are doing this research study to look at how the medication metformin affects the cells in the body of patients with PCOS. Specifically, the investigators will look at how metformin affects the mitochondria. Mitochondria are the part of cells that produce fuel (energy) for other cells and play a role in metabolism. The investigators would like to see whether there is a relationship between mitochondrial activity and symptoms of polycystic ovary syndrome (PCOS) before and after treatment with metformin. They would also like to study whether genes affect the response to metformin in women with PCOS.

Detailed description: Women who are eligible to enroll in this study will be treated with the medication metformin for 12 weeks. Before and after treatment with metformin, the following will be assessed:
  -  Weight, blood pressure, waist circumference
  -  Lipids (cholesterol)
  -  Hormone levels (including testosterone and other androgens)
  -  IV glucose tolerance test (to assess for early evidence of insulin resistance)
  -  Effect of metformin on muscle mitochondria (this will involve one MRI scan and one muscle biopsy each before and after treatment with metformin)
  Ovulation will be closely monitored at least twice a month with pelvic ultrasounds and blood tests for estrogen and progesterone levels.

Eligibility: Inclusion Criteria:
  -  Polycystic ovary syndrome
  -  No hormonal or antidiabetic medications for 1 month
  -  Good general health
  Exclusion Criteria:
  -  Smoker
  -  Acute infection or chronic disease
  -  Diabetes
  -  Pregnant or trying to get pregnant over next half year
  -  Bleeding disorders
  -  Any metal or foreign implants (e.g., aneurysm clips, ear implants, heart pacemakers or defibrillators)

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: PET CT With HX4 in Cervix Cancer

Summary: The aim of this study is:
  1. to determine if tumor hypoxia can be accurately visualised with [18F]HX4 PET imaging in cervix cancer,
  2. to correlate the [18F]HX4 PET images with blood and tissue markers,
  3. to investigate the quality and optimal timing of [18F]HX4 PET images,
  4. to compare [18F]HX4 PET uptake with [18F]FDG PET uptake before and after treatment and
  5. analyze correlation with responses

Detailed description: Tumor hypoxia is the situation where tumor cells are or have been deprived of oxygen. Hypoxic tumor cells are usually more resistant to radiotherapy and chemotherapy and more likely to develop metastasis. In Cervix cancer, tumor hypoxia is known to be an important prognostic factor for long term survival. [18F]HX4 is being developed as a diagnostic radiopharmaceutical for PET imaging to find a marker for hypoxia that can be used in standard clinical practice. Current hypoxia tracers lack reliable image quality and kinetics. Because of the short half life and clearance, the investigators expect that [18F]HX4 will have a higher tumor to background ratio than current nitro-imidazole hypoxia markers such as [18F]-misonidazole. In a recent phase 1 clinical study from van Loon et al, PET-imaging with [18F]HX4 was feasible without any toxicity. The clinical use of a reliable, non-invasive and easy to use hypoxia imaging agent could allow selection of patients most likely to benefit from hypoxia modifying therapies.

Eligibility: Inclusion criteria
  -  Histologically confirmed cervix carcinoma (squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma)
  -  tumor stages FIGO IB - IVA
  -  WHO performance status 0 to 2
  -  Scheduled for primary curative radiotherapy (either or not combined with chemotherapy or hyperthermia)
  -  No previous surgery to the Cervix
  -  No previous radiation to the Cervix
  -  The patient is willing and capable to comply with study procedures
  -  18 years or older
  -  Written informed consent before patient registration
  Exclusion criteria
  -  Recent (< 3 months) myocardial infarction
  -  Uncontrolled infectious disease
  -  Pregnant or breast feeding and/or not willing to take adequate contraceptive measures during the study

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer

Summary: This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy. The study will use a central randomization with a dynamic allocation using biased coin minimization.


Eligibility: Inclusion Criteria:
  1. FIGO stage (2008): IIIB, cervical cancer;
  2. Pathologically confirmed squamous cell carcinoma of the cervix;
  3. Patients with treatment-naive cervical cancer;
  4. Patients without enlargement (≥15 mm in the short axis) in the lower abdominal para-aortic lymph node confirmed by CT scanning (Patients need not repeat CT scan at screening if CT data [film or electronic image] within 30 days before informed consent are available and can be provided for central imaging assessment);
  5. Patients ≥21, ≤79 years of age at informed consent;
  6. Patients for whom it is considered possible to carry out intracavitary radiation in radiotherapy;
  7. Eastern Cooperative Oncology Group Performance Status: 0-2;
  8. Patients with the following organ functions; (1) WBC ≥3,000/mm3; (2) Platelet count ≥100,000/mm3; (3) Hemoglobin ≥9.5 g/dL (correction by blood transfusion is allowed); (4) Total bilirubin ≤ three (3) times the upper limit of reference value at the clinical testing laboratory; (5) AST, ALT ≤ three (3) times the upper limit of reference value at the clinical testing laboratory; (6) Renal function:
  1. If combination therapy with cisplatin is planned, creatinine clearance: ≥50 mL/min;
  2. If combination therapy with cisplatin is not planned, creatinine ≤ twice (2) the upper limit of reference value at the clinical testing laboratory;
  9. Patients who are willing to give informed consents. "

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

Summary: This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL). The study will also characterize the pharmacokinetic (PK) profile of GS-9901, determine the appropriate dosing regimen of GS-9901 for use in future clinical trials, and to evaluate the efficacy of GS-9901 monotherapy in adults with FL, MZL, CLL, or SLL.


Eligibility: Inclusion Criteria:
  -  Diagnosis of FL, MZL, SLL, or CLL (meeting International Workshop on CLL [IWCLL] Criteria, 2008) as documented by medical records and with histology based on criteria established by the World Health Organization
  -  FL Grades 1, 2, or 3a
  -  SLL with absolute lymphocyte count of < 5 x 10^9/L at initial diagnosis
  -  MZL (splenic, nodal, or extra-nodal)
  -  Prior treatment for FL or CLL/SLL with ≥ 1 prior chemotherapy-based or immunotherapy-based regimen with no approved therapies available
  -  Presence of radiographically measurable lymphadenopathy or extra nodal lymphoid malignancy
  -  All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], or bone marrow parameters [any of Grade 1, 2, or 3 permitted)
  -  Eastern Cooperative Oncology Group (ECOG) ≤ 2
  -  Able to provide written informed consent
  Exclusion Criteria:
  -  History of lymphoid malignancy other than FL, MZL, SLL, or CLL
  -  History of myelodysplastic syndrome
  -  History of a non-lymphoid malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to start of study therapy, or any other cancer that has been in complete remission for ≥ 5 years
  -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study therapy
  -  Ongoing drug-induced pneumonitis
  -  Ongoing inflammatory bowel disease
  -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  -  History of prior therapy with any inhibitor of serine/threonine kinase (AKT), Bruton tyrosine kinase (BTK), Janus kinase (JAK), mammalian target of rapamycin (mTOR), phosphatidylinositol 3-kinase (PI3K), or spleen tyrosine kinase (SYK)
  -  Ongoing immunosuppressive therapy, including systemic corticosteroids for treatment of lymphoid malignancy

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Sonoelastography of the Uterine Cervix Before Induction of Labor

Summary: The investigators aim to measure sonoelastographically the elasticity of the uterine cervix in pregnant patients at term before induction of labor and compare between patients with successful and failed inductions.

Detailed description: Softening of the uterine cervix in pregnant patients at term causes changes in its elasticity.these changes may affect success or failure in induction of labor.The elasticity of the uterine cervix is usually evaluated clinically and subjectively by vaginal examination (bishop's score) which is not very predictive.We aim to measure the elasticity quantitatively and objectively.The difference in strain, in the area of the internal os , is often illustrated by a color map, where low stiffness (soft tissue) is indicated in red, middle stiffness is in green and high stiffness (hard tissue) is in blue.The color maps will be compared between patients with successful and failed inductions.

Eligibility: Inclusion Criteria:
  -  pregnant patients before induction of labor
  Exclusion Criteria:
  -  pregnant patients undergoing caesaren section following induction of labor not in active labor

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term

Summary: In this study the investigators aim to compare the cervical dilation time in pregnant patients at term who had clinical evaluation of the cervical consistency with patients who had also quantitative measurement of the cervical elasticity in .

Detailed description: Softening of the uterine cervix in pregnant patients at term is usually evaluated clinically by subjective vaginal manual examination (Bishop's score).One of the variables of the score is cervical consistency which is considered important factor.The cervical consistency is described as soft,medium or stiff.However, the digital assessment of consistency is subjective and less reproducible.The Bishop's score also gives information about expected duration of labor after induction. The consistency of the uterine cervix can also be evaluated objectively sonoelastographically by measuring the cervical elasticity.This is illustrated by a color map, where low stiffness (soft tissue) is indicated in red, middle stiffness is in green and high stiffness (hard tissue) is in blue.In this study we aim to compare the cervical dilation time between the clinical evaluation of the cervical consistency and the quantitative measurement of the cervical elasticity in pregnant patients at term.

Eligibility: Inclusion Criteria:
  -  Pregnant patients at term
  Exclusion Criteria:
  -  Various pregnancy complications

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

Summary: 100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years. This data will be used to determine the pancreatic cancer and precancerous lesion detection rate in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers or to biomarkers only.


Eligibility: Inclusion Criteria:
  -  Have a family history of PC as listed below or who have one of the following syndromes: Peutz-Jeghers syndrome - STK11; BRCA 1 and 2; PALB2; ATM; FAMMM / P16; HNPCC (Lynch) / MMR genes; Hereditary pancreatitis - PRSS1
  -  Individuals with three or more affected blood relatives (1st, 2nd or 3rd degree)
  -  Individuals with two or more affected blood relatives with PC, with at least one affected FDR, should be considered for screening.
  -  Patients with a history of Peutz-Jeghers syndrome should be screened, regardless of family history of PC.
  -  Patients with a known p16 (FAMMM syndrome) with one affected 1st or 2nd degree relative will be considered for screening.
  -  Patients with a known BRCA1 or BRCA2 mutation with one affected 1st or 2nd degree relative should be considered for screening.
  -  Patients with a known PALB2 mutation with one affected family member should be considered for screening.
  -  Patients with a known Mismatch-repair gene-mutation carriers (Lynch syndrome) with one affected family member should be considered for screening.
  Exclusion Criteria:
  -  Not candidates for surgery

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Feasibility Study: Conservative Treatment in Cervical Cancer

Summary: Currently conservative treatment for patients of childbearing affected by cervical cancer is reserved for women with FIGO stage IA2 - IB1 with tumor size less than 2 cm . The trachelectomy and the cone biopsy with pelvic lymphadenectomy are the choice for these patients wishing to preserve their reproductive function.
  In this context , recently literature show the results about the use of neo-adjuvant chemotherapy about the reduction of tumor volume and therefore the magnitude of the subsequent surgical treatment (including patients with tumors larger than 2 cm ). So it becomes crucial a prospective analysis on the possibility to include in this type of treatment patients with stage IB1 and IIA1 with tumor size greater than 2 cm ( up to 4 cm ) .
  The current study , in fact , would like to do a prospective evaluation on the advantages of neo-adjuvant chemotherapy in the possibility of broadening the inclusion criteria to conservative treatment in women , suffering from cervical cancer, stage IB1 and IIA1 ( with tumor volume between 2 and 4 cm) and wishing to preserve their reproductive function.

Detailed description: The investigators would like to be conservative in young patients affected by early stage cervical cancer.

Eligibility: Inclusion Criteria:
  -  Squamous cervical cancer or adenocarcinoma in FIGO stage IB1-IIA, tumor volume between > 2 and ≤ 4 cm (instrumental evaluation).
  -  Informed consensus
  -  Childbearing
  -  Fertility (through US and ormonal withdrawal pre - e post neoadjuvant chemotherapy
  -  ASA (American Society of Anesthesiologist) Class < 2
  Exclusion Criteria:
  -  ongoing pregnancy

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study

Summary: This study will investigate the types of HPV in samples from women with cervical pre-cancer and cancer and gather information to help investigate the impact of HPV vaccination in Switzerland.


Eligibility: Inclusion Criteria:
  -  Participant is willing and able to give informed consent for participation in the study.
  -  Participant is literate in German, French, Italian or English.
  -  Female, aged 18 years or above.
  -  Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
  -  Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Comparison of Class II and Class III Hysterectomy in Early Stage Cervical Cancer Cervical Cancer

Summary: Based on the value-based medicine, a randomized clinical trial was conducted to compare the role of class II and class III hysterectomy in patients with low risk early staged cervical cancer (defined as tumor lesions less than 2cm with less than 50% stromal invasion).

Detailed description: This is a 1:1 multi-center randomized trial with class II hysterectomy plus node dissection as the experimental arm, and class III hysterectomy plus pelvic node dissection as the control arm. Primary endpoints are: (1). 3-year diseases-free survival (DFS) rate; (2) the rates of treatment-related toxicity; (3) post-operation QoL (including sexual function) and (4) treatment costs. Secondary endpoints are：(1) the rates of pelvic and/or extra-pelvic relapse; (2) overall survival(OS) rate; (3) the numbers of retroperitoneal node dissection, and (4) the rates of parametrial, margins and pelvic/para-aortic nodes involvement.

Eligibility: Inclusion Criteria:
  1. Stage IA2 and small IB1 <2 cm
  2. Less than 50% stromal invasion based on MRI OR 10mm stromal invasion based on the pathology measurement of the LEEP/cone specimen
  3. Squamous OR adenocarcinoma OR adenosquamous
  4. Grade 1, 2 and 3
  5. Lymph-vascular space invasion (LVSI): presence or absence
  6. Diagnosis confirmed by LEEP/cone/cervical biopsy
  7. Pelvic MRI in patients with involved cone/LEEP margins and those who had cervical biopsy only
  8. Abdomino-pelvic CT scan in patients with negative LEEP-cone margins
  9. No contraindications to surgery
  10. No desire to preserve fertility
  11. Informed consent
  Exclusion Criteria:
  1. High-risk histology types (clear cell, small cell etc)
  2. Evidence of lymph node metastasis on preoperative imaging
  3. Stage 1A1
  4. Neo-adjuvant chemotherapy
  5. Pregnancy
  6. Desire to preserve fertility

Relevance to patient case: not relevant